NCT05665348View on ClinicalTrials.gov

Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

574

Participants

Timeline

Start Date

March 9, 2023

Primary Completion Date

February 1, 2025

Study Completion Date

April 1, 2026

Conditions
HCC - Hepatocellular CarcinomaMetastatic CancerMetastatic Tumor
Interventions
DRUG

Ipilimumab Injection

Administration of a combine treatment by atezolizumab and bevacizumab, with addition of ipilimumab for patients enrolled in the experimental arm

DRUG

Atezolizumab Injection

One of the standard treatment's product for HCC management

DRUG

Bevacizumab

One of the standard treatment's product for HCC management

Trial Locations (8)

Unknown

RECRUITING

Chu Henri Mondor, Créteil

RECRUITING

Chu Francois Mitterand, Dijon

RECRUITING

Chu Dupuytren, Limoges

RECRUITING

Chu La Croix Rousse, Lyon

RECRUITING

Chu L'Archet, Nice

RECRUITING

Chu La Pitie Salpetriere, Paris

RECRUITING

Chu Saint Antoine, Paris

RECRUITING

Chu Haut Leveque, Pessac

All Listed Sponsors
lead

Federation Francophone de Cancerologie Digestive

OTHER